All In Biotech

Drug safety

How to search FAERS, FDA's adverse event database

How to search FAERS, the FDA Adverse Event Reporting System: three ways to look up reports for a drug, how to read the counts, and what the data cannot show.

By the All In Biotech editorial team · Published November 18, 2026 · 5 min read

FAERS, the FDA Adverse Event Reporting System, holds reports of suspected side effects, medication errors and product problems for drugs and therapeutic biologics. You can search it free in three ways: FDA's FAERS Public Dashboard, the openFDA adverse event API, or summary tools such as this site's FAERS Monitor. The reports are useful for spotting patterns, but they cannot show that a drug caused an event or how often it happens.

This guide covers how to search, how to read the results, and the limits to keep in mind.

What FAERS is

FAERS is the database FDA uses for postmarketing safety surveillance of drugs and therapeutic biologics. FDA's pages now describe it as part of the FDA Adverse Event Monitoring System (AEMS), which consolidates several of the agency's reporting systems, but the reports and public tools are the same.

Reports come from two routes:

  • Manufacturers are required by FDA regulations to submit the adverse event reports they receive. Serious and unexpected events must be reported within 15 days.
  • Health professionals and consumers can report voluntarily through MedWatch.

Each report lists one or more drugs, one or more reactions coded in MedDRA (a standard medical dictionary), and, where known, the patient's age and sex, the outcome and the reporter type. As of November 2026, FAERS holds about 21 million reports in total.

Vaccines are not in FAERS. Their reports go to VAERS, run jointly by FDA and CDC.

Option 1: the FAERS Public Dashboard

FDA's FAERS Public Dashboard is the official way to browse the data without code.

  1. Open the dashboard from FDA's page and accept the disclaimer.
  2. Use the search box to find a product by brand name or active ingredient.
  3. Read the summary panels: total reports, serious reports and deaths, reports by year, by reporter type, by age and sex.
  4. Open the reactions view to see the most reported MedDRA terms.
  5. To read individual cases, drill into the case list. Case-level detail is limited to protect privacy.

The dashboard is updated quarterly. For bulk analysis, FDA also publishes the quarterly data files for download.

Option 2: openFDA

openFDA offers the same reports through a free drug adverse event API. It suits people who want to count reactions, filter by date or outcome, or build their own analysis. The API can count by any field, for example the top reactions for a drug, or reports per year.

Two points catch people out. First, drug names in reports are written by the reporter, so the same drug appears under brand names, generic names and misspellings. openFDA adds harmonized fields, including the application number, for reports it can match. Second, openFDA processes its copy of the data separately, so counts can differ slightly from the dashboard.

Option 3: this site's FAERS Monitor

The FAERS Monitor on this site queries openFDA for a brand-name drug and shows:

  • the total number of reports, how many were serious, how many involved hospitalization and how many reported a death from any cause;
  • the most reported reactions;
  • reports by year received;
  • a proportional reporting ratio (PRR) screen, which flags reactions that appear more often in the drug's reports than in the rest of FAERS.

It counts reports that name the drug's application number or its brand name. Reports on generic versions are filed under their own applications.

Worked example: Ozempic

In openFDA data as of November 2026, reports naming Ozempic (both of its NDAs plus the brand name) total 70,721. Of those:

MeasureReports
All reports70,721
Serious35,100
Hospitalization13,974
Death reported (any cause)1,193
Nausea10,175
Off label use7,482
Vomiting6,675
Diarrhoea6,326

The top reactions match the gastrointestinal effects listed on the label. "Off label use" is a reported term, not a side effect: it records that the drug was used outside its approved indications.

The disproportionality screen flags impaired gastric emptying, with 4,024 reports and a PRR of about 124, meaning the term appears far more often in Ozempic reports than in other FAERS reports. Constipation (PRR 6.4) and decreased appetite (6.1) are also flagged.

What this shows is a reporting pattern worth looking at. It does not show how many people taking Ozempic experienced these effects, and the 1,193 death reports record that a death occurred, not that the drug caused it. Reports of a widely used drug also rise with prescriptions and media coverage.

How to read FAERS counts

  • Serious has a regulatory meaning: the outcome was death, a life-threatening event, hospitalization, disability, a birth defect or another medically important event. It does not mean the reaction was severe in the everyday sense.
  • One report, several drugs. A report can name many drugs. The suspect drug is the one the reporter thought responsible, but concomitant drugs are listed too, and some tools count both.
  • Duplicates. The same case can be reported by a patient, a doctor and the manufacturer. FDA tries to merge duplicates, but some remain.
  • Year received, not year of the event. Reports by year reflect when FDA received them. Lawsuits and news coverage can produce bursts of older cases.
  • Indication terms. Reactions that match the disease being treated, such as "disease progression" for a cancer drug, often appear at the top. That is expected and not a signal.

What FAERS cannot tell you

FDA's own disclaimers make the same points:

  1. Causation. A report reflects a suspicion. FDA does not require that a causal relationship be shown before accepting a report.
  2. Incidence. There is no denominator. FAERS does not know how many people took the drug, so report counts cannot be turned into rates or compared directly between drugs.
  3. Completeness. Most adverse events are never reported. Reporting varies with how new the drug is, how widely it is used, publicity and litigation.
  4. Quality. Many reports lack key details such as dose, timing or medical history.

For incidence, the better sources are the drug's label, which reports adverse reaction rates from clinical trials, and published studies. The drug label guide explains where those tables are.

From reports to safety signals

FDA reviews FAERS data to find potential safety signals, then investigates them with other evidence such as clinical trial data, medical literature and other databases. When a signal holds up, FDA can update the label, issue a Drug Safety Communication or require further studies. FDA also publishes quarterly lists of potential signals of serious risks that it has identified through FAERS.

The statistics behind signal screening, including the PRR thresholds used on this site, are explained in proportional reporting ratio explained. For the wider set of public databases that pair with FAERS, see free drug databases.

Reporting an adverse event

If you have experienced a side effect, talk to a health professional first. You or your clinician can report it to FDA through MedWatch. FDA keeps the identities of reporters and patients confidential, and every report adds to the data FDA uses to monitor drug safety.

Frequently asked questions

What is FAERS?
FAERS is FDA's database of reports of suspected adverse events, medication errors and product problems for drugs and therapeutic biologics, submitted by manufacturers, health professionals and patients.
Does a FAERS report prove a drug caused a side effect?
No. A report means someone suspected a link, and FDA does not require proof of causation before a report is entered.
Can FAERS tell me how common a side effect is?
No. FAERS has no count of how many people took the drug, and most adverse events are never reported, so it cannot give rates.
Are vaccines in FAERS?
No. Vaccine adverse events are reported to the separate Vaccine Adverse Event Reporting System, VAERS.

For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.

Keep reading